JW Pharmaceutical Corp (001065) - Total Liabilities

Latest as of June 2026: ₩249.96 Billion KRW ≈ $169.39 Million USD

Based on the latest financial reports, JW Pharmaceutical Corp (001065) has total liabilities worth ₩249.96 Billion KRW (≈ $169.39 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 001065 long-term investments to assets to see how much of total assets are deployed in long-term investments.

JW Pharmaceutical Corp - Total Liabilities Trend (2014–2025)

This chart illustrates how JW Pharmaceutical Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see JW Pharmaceutical Corp balance sheet assets.

JW Pharmaceutical Corp Competitors by Total Liabilities

The table below lists competitors of JW Pharmaceutical Corp ranked by their total liabilities.

Company Country Total Liabilities
Zhejiang Dilong New Material Co Ltd
SHE:002247
China CN¥281.35 Million
Discount Investment Corp Ltd
TA:DISI
Israel ILA18.71 Billion
Perdana Karya Perkasa Tbk
JK:PKPK
Indonesia Rp486.15 Billion
Great Tree Pharmacy Co Ltd
TWO:6469
Taiwan NT$9.76 Billion
Cantor Equity Partners II, Inc.
NASDAQ:CEPT
USA $6.13 Million
Heilongjiang Interchina Water Treatment Co Ltd
SHG:600187
China CN¥305.90 Million
RiverNorth Flexible Municipal Income Fund II Inc
NYSE:RFMZ
USA $244.79 Million

Liability Composition Analysis (2014–2025)

This chart breaks down JW Pharmaceutical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 001065 net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.56 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.61 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how JW Pharmaceutical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for JW Pharmaceutical Corp (2014–2025)

The table below shows the annual total liabilities of JW Pharmaceutical Corp from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩235.90 Billion
≈ $159.87 Million
-14.25%
2024-12-31 ₩275.11 Billion
≈ $186.44 Million
-27.53%
2023-12-31 ₩379.60 Billion
≈ $257.25 Million
-5.62%
2022-12-31 ₩402.21 Billion
≈ $272.57 Million
-9.52%
2021-12-31 ₩444.51 Billion
≈ $301.24 Million
+30.12%
2020-12-31 ₩341.62 Billion
≈ $231.51 Million
-0.44%
2019-12-31 ₩343.12 Billion
≈ $232.52 Million
+2.83%
2018-12-31 ₩333.68 Billion
≈ $226.13 Million
-7.34%
2017-12-31 ₩360.10 Billion
≈ $244.03 Million
-3.91%
2016-12-31 ₩374.76 Billion
≈ $253.97 Million
-3.43%
2015-12-31 ₩388.07 Billion
≈ $262.99 Million
+5.11%
2014-12-31 ₩369.22 Billion
≈ $250.21 Million
--

About JW Pharmaceutical Corp

KO:001065 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$302.34 Million
₩446.13 Billion KRW
Market Cap Rank
#14883 Global
#476 in Korea
Share Price
₩22200.00
Change (1 day)
+1.83%
52-Week Range
₩19800.00 - ₩29850.00
All Time High
₩88605.96
About

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more